Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.

Stable lipid-comprising drug delivery complexes and methods for their production

This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.

Nucleic acid ligand complexes

The present invention discloses compositions useful for transfecting eukaryotic cells comprising nucleic acid complexes with peptides, proteins or protein fragments, wherein the peptide is optionally covalently couple to a DNA-binding group, and cationic lipids useful for transfecting eukaryotic cells. Methods for the preparation of transfecting compositions and use as intracellular delivery agents and extracellular targeting agents are also disclosed.

Peptide-enhanced cationic lipid transfections

Multilayered particulate materials are formed by coating a particulate substrate with a metal and adsorbing an organic layer comprising a recognition moiety onto the metal film The recognition moiety interacts with an analyte of interest allowing for its detection, purification, etc Suitable recognition moieties can be selected from a range of species including, small molecules, polymers and biomolecules and the like The novel particulate materials of the invention can be utilized in an array of methods including, ion-exchange, ion-selective ion-exchange, assays, affinity dialysis, size exclusion dialysis, as supports in solid phase synthesis, combinatorial synthesis and screening of compound libraries and the like

Support for high performance affinity chromatography and other uses

A self-assembling polynucleotide delivery system comprises a dendrimer polycation aiding in the delivery of the polynucleotide to a desired address, and optionally other agents such as DNA masking agents, cell recognition agents, charge-neutralization agents, membrane-permeabilization agents, and subcellular-localization agents.

Self-assembling polynucleotide delivery system comprising dendrimer polycations

This invention provides a self-assembling polynucleotide delivery system comprising components aiding in the delivery of the polynucleotide to the desired address which are associated via noncovalent interactions with the polynucleotide. The components of this system include DNA-masking components, cell recognition components, charge-neutralization and membrane-permeabilization components, and subcellular localization components. Specific compounds useful in this system are also provided.

Jean Haensler

Papers

Self-assembling polynucleotide delivery system

Self-assembling polynucleotide delivery method